The standard chemotherapy treatments had not significantly changed for almost 40 years [9], until the recent introduction of several new therapies: Midostaurin for treating fms-like tyrosine kinase 3 (FLT3)-mutated AML, enasidenib for relapsed or refractory AML with an isocitrate dehydrogenase-2 (IDH2) mutation, CPX-351 for newly diagnosed therapy-related patients or with myelodysplasia-related changes, gemtuzumab ozogamicin (GO) for treatment of adults with newly diagnosed CD33+ AML, and ivosidenib for relapsed or refractory AML with an IDH1 mutation [10,11,12,13]. The gene discussed is FLT3; the disease is acute myeloid leukemia.